Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
NCT ID: NCT00109681
Last Updated: 2010-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2005-04-30
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
NCT01437878
Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
NCT00439543
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
NCT00453414
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
NCT00414687
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
NCT00185315
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iloprost Inhalation Solution (Ventavis)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of elevated pulmonary pressures
* Six minute walk distance between 50-380
* NYHA functional class II - IV
Exclusion Criteria
* Significant chronic obstructive pulmonary disease
* History of thromboembolic disease within the previous year
* Awaiting lung transplantation within next 36 weeks
* Active lung infection
* Survival prognosis of less than 1 year
* Significant left-sided heart failure, active coronary artery disease
* Clinically relevant liver disease
* Concurrent medications: epoprostenol, treprostinil, bosentan, PDE-5 inhibitor, investigational agents
40 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Actelion
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Pennington, MD
Role: STUDY_DIRECTOR
CoTherix
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
UCLA School of Medicine
Los Angeles, California, United States
University of California, San Diego
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
University of Miami
Miami, Florida, United States
The University of Chicago
Chicago, Illinois, United States
University of Iowa College of Medicine
Iowa City, Iowa, United States
Tulane University
New Orleans, Louisiana, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Mount Sinai Medical Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical
Nashville, Tennessee, United States
Baylor College of Medicine
Houston, Texas, United States
University of Texas Health Center at Tyler
Tyler, Texas, United States
Inova Research Center
Church Falls, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACTIVE C200-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.